Palmer C S, Niparko J K, Wyatt J R, Rothman M, de Lissovoy G
MEDTAP International, Bethesda, MD 20814, USA.
Arch Otolaryngol Head Neck Surg. 1999 Nov;125(11):1221-8. doi: 10.1001/archotol.125.11.1221.
Prior clinical studies have indicated that cochlear implantation provides benefits to individuals with advanced sensorineural hearing loss who are unable to gain effective speech recognition with hearing aids.
To determine the cost per quality-adjusted life-year (QALY) for adults receiving multichannel cochlear implants.
Prospective 12-month multicenter study using preference-based quality-of-life measures and total cost determinations, comparing profoundly hearing-impaired adult subjects with and without cochlear implants.
Hospital-based and patient-resource clinics.
Severely to profoundly hearing-impaired adult recipients of a cochlear implant and adults eligible for the device who had not yet received it.
Clinical assessment of implant participants included medical and audiologic (speech understanding) data at the time of enrollment, 6 months, and 12 months. All participants' health-utility was assessed at the time of enrollment, 6 months, and 12 months using the Health Utility Index. One-year medical resource utilization and cost data included bills related to implants, patient diaries, charge estimates from clinical sites, and published literature. A decision model was developed to determine cost per QALY.
Of the 84 enrolled adults, 62 (75%) completed the study. Mean health-utility scores at the time of enrollment were identical between groups. The marginal 12-month health-utility gain for implant recipients was 0.20; 90% of this improvement was achieved within 6 months. For patients with a mean 22-year life expectancy, the marginal cost per QALY was $14,670.
Overall, multichannel cochlear implants significantly improved recipients' performance on measures of speech understanding and ratings of health-utility within 6 months of implantation. The multichannel cochlear implant yielded a very favorable cost per QALY.
先前的临床研究表明,人工耳蜗植入可为重度感音神经性听力损失且无法通过助听器有效获得言语识别能力的个体带来益处。
确定接受多通道人工耳蜗植入的成年人每质量调整生命年(QALY)的成本。
一项前瞻性的为期12个月的多中心研究,采用基于偏好的生活质量测量方法和总成本测定方法,比较植入和未植入人工耳蜗的重度听力受损成年受试者。
医院及患者资源诊所。
接受人工耳蜗植入的重度至极重度听力受损成年受助者,以及符合植入条件但尚未接受植入的成年人。
植入人工耳蜗参与者的临床评估包括入组时、6个月和12个月时的医学和听力学(言语理解)数据。使用健康效用指数在入组时、6个月和12个月时评估所有参与者的健康效用。一年的医疗资源利用和成本数据包括与植入物相关的账单、患者日记、临床机构的费用估算以及已发表的文献。开发了一个决策模型来确定每QALY的成本。
84名入组成年人中,62名(75%)完成了研究。两组入组时的平均健康效用得分相同。植入人工耳蜗者12个月的边际健康效用增益为0.20;其中90%的改善在6个月内实现。对于平均预期寿命为22年的患者,每QALY的边际成本为14,670美元。
总体而言,多通道人工耳蜗植入在植入后6个月内显著改善了接受者的言语理解能力和健康效用评分。多通道人工耳蜗植入产生了非常有利的每QALY成本。